By 2024, frequently cited burst keywords included “resistance,” “gene expression,” “immune infiltration,” “tumor microenvironment,” “efficacy,” “checkpoint,” “PD-L1,” “sunitinib,” “1st line treatment,” “cabozantinib,” and “axitinib,” indicating current research frontiers in PD-1/PD-L1 immunotherapy for RCC. This evidence concerns the gene CD274 and renal cell adenocarcinoma.